Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
RESEARCH TOOLSreports
Holding TLSI?
Track your performance easily
TLSI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.32 - $10.42
Previous Close$4.48
Volume190.31K
Average Volume (3M)47.38K
Market Cap
$131.32M
Enterprise Value$136.12M
Total Cash (Recent Filing)$16.48M
Total Debt (Recent Filing)$21.29M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 12, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.51
Shares Outstanding29,311,498
10 Day Avg. Volume85,774
30 Day Avg. Volume47,381
Standard Deviation0.19
R-Squared0.01
Alpha-0.00786
Financial Highlights & Ratios
Price to Book (P/B)-5.46
Price to Sales (P/S)5.31
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.21
Enterprise Value/Gross Profit8.56
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$12.25Price Target Upside173.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
TriSalus Life Sciences News
Bulls Say, Bears Say
Bulls Say
Earnings2Q24 total revenue of $7.4M beat estimates and consensus, highlighting the company's strong financial performance.
Market ExpansionTriNav commercialization has grown at a ~50% CAGR, showing significant market traction and potential for future growth.
Product DevelopmentThe adoption of TriNav for TACE/TARE procedures continued to accelerate with revenue reported at 88% gross margin.
Bears Say
Adverse EventsThree patients (13%) reported serious treatment-related adverse events (SAEs) and one presented dose-limiting toxicity (DLT); all were in Cohort C.
Product DevelopmentTriSalus to deprioritize nelitolimod in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
Revenue ForecastThe risk-adjusted revenues ascribed to nelitolimod decreased to $449M (previously $746M) and royalty revenue decreased to $36M (previously $56M) by FY34.
---
Ownership Overview
32.20% Insiders
1.82% Mutual Funds
4.36% Other Institutional Investors
61.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $3.32 and its highest was $10.42 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
Currently, no data Available
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Nov 12, 2024 which is in 7 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on Aug 15, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.249.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -$0.34.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 29,311,499 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 0.684%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Among the largest hedge funds holding TriSalus Life Sciences’s share is Duquesne Family Office LLC. It holds TriSalus Life Sciences’s shares valued at 2M.
---
TriSalus Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.25 (173.44% Upside)
$12.25 (173.44% Upside)
Blogger Sentiment
Bearish
TLSI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 325.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
165.01%
Trailing 12-Months
Company Description
TriSalus Life Sciences
MedTech Acquisition Corp is a blank check company.
---
TLSI Earnings Call
Q2 2024
0:00 / 0:00
---
TLSI Stock 12 Month Forecast
Average Price Target
$12.25
▲(173.44% Upside)
Technical Analysis
Best Analysts Covering TLSI
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-31.28%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -31.28% per trade.
---